Materiovigilance Programme Of India (MvPI) Platform:
The Drugs Controller General of India (DCGI), through a circular, has directed all device license holders and manufacturers to report any adverse events on the Materiovigilance Programme of India (MvPI) platform to mitigate risks and ensure public health safety.
- MvPI was launched in 2015, and is overseen by the Indian Pharmacopoeia Commission since 2018.
- It serves as the National Coordination Centre, focusing on monitoring Medical Device-associated Adverse Events (MDAE) and raising awareness among healthcare professionals.
- MDAE reports can be submitted by various stakeholders, including clinical specialists, biomedical engineers, nurses, pharmacists, and patients.
- The Drugs Controller General of India (DCGI) heads the Central Drugs Standard Control Organization, overseeing the approval of licenses for specified drug categories in India, including blood products, vaccines, and IV fluids.
- DCGI operates under the Ministry of Health & Family Welfare and establishes standards for drug manufacturing, sales, import, and distribution in the country.
